ISRCTN68324970招募中未知
on-interventional safety study on the tolerability and safety of octagam® 5%, octagam® 10% and panzyga®
Octapharma GmbH (Germany)0 个研究点目标入组 5,000 人开始时间: 2013年11月19日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 5,000
研究概览
简要总结
- 2016 results in: https://www.ncbi.nlm.nih.gov/pubmed/27719744 .
研究设计
- 研究类型
- Observational
入排标准
- 性别
- All
入选标准
- •Patients of any age and gender, who receive treatment with octagam® 5%, octagam® 10% or panzyga®
排除标准
- •Patients with known contraindications as specified in the Summary of Product Characteristics (SPC)
研究者
相似试验
已完成
不适用
The tolerability of Octagam® 5% and Octagam® 10%Any indication, age, or treatment regimen in which Octagam is prescribedHaematological DisordersISRCTN02245668Octapharma AG (Switzerland)1,000
已完成
1 期
A phase I study to assess safety and tolerability and neutralising activity of CL184 in healthy volunteersInfections and InfestationsRabiesISRCTN18660493Crucell Holland BV (The Netherlands)57
已完成
4 期
Tolerability and completion of Maraviroc compared to Kaletra® in combination with Truvada® for HIV Post Exposure ProphylaxisHIVInfections and InfestationsISRCTN63350011Central and North West London NHS Foundation Trust (UK)280
已完成
1 期
A phase Ib study to assess safety and tolerability and neutralising activity of CL184 in healthy volunteersRabiesISRCTN12693237Crucell Holland BV (The Netherlands)44
已完成
2 期
A Study of Safety, Tolerability, and Clinical Activity of MEDI4736 and Tremelimumab Administered as Monotherapy and in Combination to Subjects With Unresectable Hepatocellular CarcinomaHepatocellular CarcinomaJPRN-jRCT2080223264AstraZeneca40